Communiqué de presse : Sarclisa Escena de Sanofi, la formulation sous-cutanée du Sarclisa, approuvé aux États-Unis comme premier traitement anticancéreux administré via un injecteur portable

Sanofi’s Sarclisa received U.S. approval for a new subcutaneous formulation, positioned as the first anti-cancer treatment administered via a portable injector. The approval supports a more convenient administration method versus traditional delivery and is a positive incremental catalyst for Sarclisa’s uptake.

Analysis

Sanofi’s Sarclisa received U.S. approval for a new subcutaneous formulation, positioned as the first anti-cancer treatment administered via a portable injector. The approval supports a more convenient administration method versus traditional delivery and is a positive incremental catalyst for Sarclisa’s uptake.